Apexigen enters collaboration with Centocor R&D for antibody discovery Apexigen, Inc. Announced today that it has entered into a collaboration and worldwide license agreement with Centocor Analysis & Development, Inc. And its own affiliates to make use of Apexigen’s proprietary therapeutic antibody systems to find and develop monoclonal antibody drugs. Apexigen’s antibody technologies create a broad diversity of antibodies with high specificity, high affinity, and unique epitopes, and can successfully generate antibodies against challenging antigens where competing technologies fail.Furthermore to streamlining the segmentation and fusion steps, another VMAT-based automated planning Component for spinal SRS can generate complicated yet highly conformal programs. This tool is specifically made to address the optimization and visualization requirements for stereotactic treatments for spine indications.. Alternative anti-inflammatory method of epilepsy management If common anticonvulsant medicines fail to manage epileptic seizures, possibly the anti-inflammatory route is the way to go then. That’s relating to Mattia Maroso and co-workers from the Mario Negri Institute for Pharmacological Analysis in Milan, Italy, who found that providing mice repeated dosages of a particular enzyme inhibitor significantly reduced both chronic epileptic activity and acute seizures.